Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.

@article{Sun2016AdditiveAE,
  title={Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.},
  author={Caixing Sun and Yang Yu and Lizhen Wang and Bin Wu and Liang Xia and Fang Feng and Zhiqiang Ling and Shihua Wang},
  journal={Journal of experimental & clinical cancer research : CR},
  year={2016},
  volume={35},
  pages={32}
}
BACKGROUND Glioblastoma is the most common and deadly primary brain tumor in adults. Low-dose,metronomic (LDM) temozolomide (TMZ) displays improved efficacy in the treatment of glioblastoma by targeting angiogenesis, but has a limited effect on recurrence. The antiangiogenesis drug ginsenoside Rg3 (RG3) is the main active ingredient of ginseng, a popular herbal medicine. METHODS Using an in vitro and a rat model of an orthotopic glioma allograft, this study was to determine whether RG3… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
9 Extracted Citations
49 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-9 of 9 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 49 references

Similar Papers

Loading similar papers…